IRCT20090808002306N6 IRCT 2021-01-29 Esfahan University of Medical Sciences Evaluation of the effect of herbal anti-asthma product along with standard treatment on the intervals and severity of moderate chronic asthma attacks in children and adolescents 6 to 18 years Clinical study of the effect of oral products of three plants: licorice (Glycyrrhiza glabra), fragrant violet (Viola adorata) and tarpaulin (Operculina turpethum) as an add-on on the intervals and severity of moderate chronic asthma attacks in children and adolescents 6 to 18 years 2020-12-21 anticipated 40 Complete https://irct.ir/trial/53295 interventional Randomization: Not randomized, Blinding: Single blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Other design features: In the design of this study, patients were divided into two categories based on the odd and even national code receiving the main drug (odd national code) and control (even national code). The first group receives anti-asthma drugs and the second group receives placebo that is exactly the same with the main drug; And one month after taking the drug, evaluations are done, Blinding description: In this study, the pulmonologist and patients are not aware of the type of drug received (main drug or placebo). The drug and the placebo are exactly the same and are distinguished only by a small code that only the researcher and responsible for data collection (student) know about. 2-3 moderate persistent asthma. Intervention 1: Intervention group: In this study, subjects in the case group received 4 packs of 30 anti-asthma pills (containing components: asparagine, hydroxycinnamic acids, glycyrrhizin, salicylic acid, methyl ester, betanitropropionic acid, poline, cycloviolasin, saponins, flavonoids, alkaloids of three plants turbid, aromatic violet and licorice) are delivered. The recipe is two morning pills and two night pills. This herbal compound is produced by Sinafaravar Pharmaceutical Company located in Najafabad, Isfahan. Intervention 2: Control group: The placebo is exactly the same as the main drug produced by Sinafaravar Pharmaceutical Company and is given to the control group for one month with the same prescription. Undecided - It is not yet known if there will be a plan to make this available Justification or reason for indecision in sharing IPD is There is no need to do this.